Albany – NY, Oct. 20, 2015 (GLOBE NEWSWIRE) — Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.
A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. A drastically different pipeline and market composition implies that the approach to pancreatic cancer treatment is changing and first-in-class innovation is playing a significant role in this.
Get Sample Research Report:
Gemcitabine based regimens continue to dominate the market, which has seen few new entrants over the past decade. The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement.
- What survival benefits do current therapies provide?
- What are the current unmet needs that the pipeline needs to address?
- The pipeline contains a plethora of molecule types and molecular targets not present on the market, including a large focus on therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
- What impact will the emergence of biologics have on the pancreatic cancer landscape?
- Will pipeline diversity translate to clinically and commercially successful therapies?
- How will the rise of novel molecular target categories, such as signal transduction, impact future treatment options?
- 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.
- Do first-in-class products show strong progression into the later stages?
- Why is the greatest number of first-in-class products seen in signal transduction?
- Numerous early-stage, first-in-class products have high promise, often supported by preclinical evidence.
- How well are first-in-class targets, such as Akt2, aligned to known disease causing pathways?
- Does scientific literature provide significant rationale for therapies acting on early-stage promising, first-in-class targets?
- What does preclinical data on Akt inhibition suggest about its potential as a target in pancreatic cancer?
- Deals for first-in-class products typically take place in earlier stages than non-first-in-class counterparts, with 79% of first-in-class licensing deals occurring in Phase I or earlier.
- To what extent does first-in-class status influence deal value?
- Can biologics command a greater deal value than other molecule types?
Browse all reports of this category at:
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
CONTACT: Mr. Nachiket Ghumare State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-621-2074 USA - Canada Toll Free: 866-997-4948 Website: http://www.researchmoz.us/